Stock NGEN NERVGEN PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Delayed Toronto S.E.
Other stock markets
 01:33:03 2024-06-10 pm EDT 		5-day change 1st Jan Change
2.2 CAD +10.00% Intraday chart for NervGen Pharma Corp. +15.18% -18.52%
Jun. 05 NervGen Pharma Corp. Approves Board and Audit Committee Elections CI
May. 16 NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NervGen Pharma Grants Stock Options
NE
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
NE
NervGen Pharma Corp. Approves Board and Audit Committee Elections
CI
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
AQ
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
NE
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
NE
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NervGen Files Management Information Circular and Announces Board of Directors Transition
NE
Nervgen Pharma Corp. Announces That Bill Radvak, Nervgen's Current Chairman and Co-Founder Will Not Stand for Re-Election and Will Transition to A Continuing Role as an Advisor to the Board
CI
NervGen Pharma : Notice of Meeting and Management Proxy Circular
PU
NervGen Engages Russo Partners LLC to Provide Public Relations Services
NE
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update
MT
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
NE
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off
AQ
NervGen Pharma Closes C$23 Million Bought Deal Financing
MT
NervGen Completes $23 Million Bought Deal Financing
NE
Canadian Investment Regulatory Organization Trade Resumption - NGEN
AQ
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units
MT
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGEN Stock
  4. News NervGen Pharma Corp.